Invetx
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
201 Washington St Ste 3930, Boston, Mass...Phone Number
(617) 880-4592Website
www.invetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Invetx
Invetx is building the world's premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The company completed a $25.5 million Series A financing in 2020 with investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. Strategic investment partners are AbCellera Biologics, a biotech company specializing in antibody discovery located in Vancouver, BC, and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is a private company headquartered in Boston, Massachusetts.Explore more
Invetx Org Chart
JT
Chief Financial Officer & Inside Counsel
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Invetx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Invetx has new funding data
Click to see if Invetx had a recent Job posting/layoffs
Check if Invetx has recently received funding, and reach out quickly before it becomes old news!
Check out if Invetx is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Invetx
Product Launch: Get notified when Invetx launches new products
Earning: See what the market has to say on Invetx recently announced quarterly report
Invetx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Invetx
Compare insights from companies similar to Invetx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Invetx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Invetx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Invetx.
Invetx financials insights
Gather financial insights about Invetx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$25.5M
2022
Series B
$60.5M
Invetx Tech Stack
A closer look at the technologies used by Invetx
Most Recent Scoops
Open Position
Person-Based
Open Position
Open Position
Open Position
Invetx News & Media
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applicationsDechra Pharmaceuticals To Acquire Invetx, For Up To $520M
Dechra Pharmaceuticals Limited, a Northwich, Cheshire, UK-based provider of a veterinary pharmaceuticals business, acquired Invetx Inc., a Boston, MA-base company which specializes in protein-based therapeutics for animal health, for up to $520M. The acquisition remains subject to antitrust approval and other customary closing conditions. In addition to the Invetx pipeline, Dechra will gain access to […] The post Dechra Pharmaceuticals To Acquire Invetx, For Up To $520M appeared first on FinSMEsNovo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
/PRNewswire/ -- Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio company, Invetx, has agreed to be...Invetx Announces Upcoming Acquisition by Dechra Pharmaceuticals, Global Leader in Animal Health
BOSTON--(BUSINESS WIRE)-- #veterinarybiotherapeutics--Invetx Inc., a pioneer in protein-based therapeutics for animal health, announced today that it has agreed to be acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free and debt-free basis. The acquisition remains subject to antitrust approval and other customary closing conditions. “We are thrilled to be joining forces with Dech
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Invetx
Sign Up For FreeTo access detailed company insights
Invetx is building the world's premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The company completed a $25.5 million Series A financing in 2020 with investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. Strategic investment... Read More
